Baird Maintains Outperform on TRACON Pharma, Lowers Price Target to $3
Portfolio Pulse from jenniferd'souza@benzinga.com
Baird analyst Joel Beatty has maintained an Outperform rating on TRACON Pharma (NASDAQ:TCON) but lowered the price target from $7 to $3.

August 15, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TRACON Pharma's price target has been lowered from $7 to $3 by Baird, although the Outperform rating is maintained.
The lowering of the price target by Baird indicates a potential decrease in the stock's value. However, the maintained Outperform rating suggests that the stock is still expected to outperform others in the market. This mixed signal could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100